Central Resistin Enhances Renal Sympathetic Nerve Activity via Phosphatidylinositol 3-Kinase but Reduces the Activity to Brown Adipose Tissue via Extracellular Signal-Regulated Kinase 1/2

Journal of Neuroendocrinology

Volumn 24, Issue 11, 2012, Pages 1432-1439

  Kosari, S ^a   Rathner, J A ^b   Badoer, E ^a  

^a RMIT UNIVERSITY   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

Brown adipose tissue; Obesity induced hypertension; Renal sympathetic nerve activity; Resistin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; RESISTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; FOOD INTAKE; HOMEOSTASIS; KIDNEY NERVE; LUMBAR SPINE; MALE; METABOLIC REGULATION; NERVE CONDUCTION; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE; THERMOGENESIS;

ADIPOSE TISSUE, BROWN; ANIMALS; ARTERIAL PRESSURE; DOWN-REGULATION; HEART RATE; INJECTIONS, INTRAVENTRICULAR; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASE; RATS; RATS, SPRAGUE-DAWLEY; RESISTIN; SYMPATHETIC NERVOUS SYSTEM; UP-REGULATION;

EID: 84867668791     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2012.02352.x     Document Type: Article

References (39)

1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
2. Morash BA, Willkinson D, Ur E, Wilkinson M. Resistin expression and regulation in mouse pituitary. FEBS Lett 2002; 3: 26-30.
3. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003; 310: 927-935.
4. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87: 2407.
5. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Perez Castrillon JL, Duenas A. Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diabetes Res Clin Pract 2009; 84: 174-178.
6. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Jankiewicz Wika J, Goch JH. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metab Clin Exp 2008; 57: 488-493.
7. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
8. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
9. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679.
10. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001; 14: 304S-309S.
11. Davy KP, Orr JS. Sympathetic nervous system behavior in human obesity. Neurosci Biobehav Rev 2009; 33: 116-124.
12. Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, Bolla G, Mancia G. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 2007; 49: 535-541.
13. Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 2010; 6: 58-67.
14. Kosari S, Rathner JA, Chen F, Badoer E. Centrally administered resistin enhances sympathetic nerve activity to the hindlimb but attenuates the activity to brown adipose tissue. Endocrinology 2011; 152: 2626-2633.
15. Vazquez MJ, Gonzalez CR, Varela L, Lage R, Tovar S, Sangiao-Alvarellos S, Williams LM, Vidal-Puig A, Nogueiras R, Lopez M, Dieguez C. Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 2008; 149: 4534-4543.
16. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2007; 293: E444-E452.
17. Enerback. Human brown adipose tissue. Cell Metab 2010; 11: 248-252.
18. Robertson SA, Rae CJ, Graham A. Induction of angiogenesis by murine resistin:putative role of PI3-kinase and MO-dependent pathways. Regul Pept 2009; 152: 41-47.
19. Rodriguez-Pacheco F, Vazquez-Martinez R, Martinez-Fuentes AJ, Pulido MR, Gahete MD, Vaudry H, Gracia-Navarro F, Dieguez C, Castano JP, Malagon MM. Resistin regulates pituitary somatotrope cell function through the activation of multiple signaling pathways. Endocrinology 2009; 150: 4643-4652.
20. Di Simone N, Di Nicuolo F, Marzioni D, Castellucci M, Sanguinetti M, D'Lppolito S, Caruso A. Resistin modulates glucose uptake and glucose transporter-1 (GLUT-1) expression in trophoblast cells. J Cell Mol Med 2009; 13: 388-397.
21. Kim M, Oh J, Sakata S, Liang L, Park W, Hajjar R, Lebeche D. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45: 270-280.
22. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006; 70: 146-157.
23. Morgan DA, Thedens DR, Weiss R, Rahmouni K. Mechanisms mediating renal sympathetic activation to leptin in obesity. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1730-R1736.
24. Rahmouni K, Morgan DA, Morgan GM, Liu X, Sigmund CD, Mark AL, Haynes WG. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest 2004; 114: 652-658.
25. Rahmouni K, Sigmund CD, Haynes WG, Mark AL. Hypothalamic ERK mediates the anorectic and thermogenic sympathetic effects of leptin. Diabetes 2009; 58: 536-542.
26. Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ, Morris A, Williams LM, Dickson SL, Dieguez C. Central administration of resistin promotes short-term satiety in rats. Eur J Endocrinol 2005; 153: R1-R5.
27. Madden CJ, Morrison SF. Neurons in the paraventricular nucleus of the hypothalamus inhibit sympathetic outflow to brown adipose tissue. Am J Physiol Regul Integr Comp Physiol 2009; 296: R831-R843.
28. Tupone D, Madden CJ, Cano G, Morrison SF. An orexinergic projection from perifornical hypothalamus to raphe pallidus increases rat brown adipose tissue thermogenesis. J Neurosci 2011; 31: 15944-15955.
29. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997; 46: 2040-2043.
30. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006; 24: 789-801.
31. DiBona GF. Neurogenic regulation of renal tubular sodium reabsorption. Am J Physiol 1977; 233: F73-F81.
32. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41: 625-633.
33. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one?Am J Physiol Regul Integr Comp Physiol 2004; 286: R803-R813.
34. Singhal NS, Lazar MA, Ahima RS. Central resistin induces hepatic insulin resistance via neuropeptide Y. J Neurosci 2007; 27: 12924-12932.
35. London SE, Clayton DF. Functional identification of sensory mechanisms required for developmental song learning. Nat Neurosci 2008; 11: 579-586.
36. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
37. Maggi CA, Meli A. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 1: General considerations. Experientia 1986; 42: 109-114.
38. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-2536.
39. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004; 43: 169-175.